Skip to content
OpenCapital
Get started

Aclaris Therapeutics ACRS Single Reportable — Research And Development Expense Personnel Charges

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Research And Development Personnel Related Costs
$26.07M+47.6%
ArriVent BioPharma, Inc. logo
AVBPSingle Reportable — Research And Development Expense Personnel Related And Other Internal Costs
$10.23M+70.3%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Research And Development Personnel Expenses
$30.65M+19.6%
Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Research And Development Expense, Personnel
$8.53M-8.6%
Theravance Biopharma logo
TBPHSingle Reportable — Research And Development Expense Salary And Wages
$2.45M-37.8%
Capricor Therapeutics logo
CAPRSingle Reportable — Research And Development Expense
$27.38M+44.7%

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%—

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0×0.0×
Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept acrs:ResearchAndDevelopmentExpensePersonnelCharges.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's single reportable — research and development expense personnel charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's single reportable — research and development expense personnel charges?
Aclaris Therapeutics (ACRS) reported single reportable — research and development expense personnel charges of $3.28M in Q1 2026.
How has Aclaris Therapeutics's single reportable — research and development expense personnel charges changed year-over-year?
Aclaris Therapeutics's single reportable — research and development expense personnel charges increased by 12.1% year-over-year, from $2.93M to $3.28M.
What does single reportable — research and development expense personnel charges mean?
Includes all compensation, benefits, and related costs for staff dedicated to research and development activities within the segment. It measures the human capital investment required to sustain the company's scientific and clinical development efforts. High personnel charges indicate a significant investment in internal expertise and specialized talent.